Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings

Merck (MRK) reported $15.81 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 1.9%. EPS of $2.13 for the same period compares to $2.28 a year ago.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $15.81 billion. With the consensus EPS estimate being $2.01, the EPS surprise was +5.97%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Merck performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Sales- Oncology- Keytruda - U.S.: $4.75 billion versus the four-analyst average estimate of $4.67 billion. The reported number represents a year-over-year change of +7.6%.Sales- Oncology- Keytruda - International: $3.21 billion compared to the $3.16 billion average estimate based on four analysts. The reported number represents a change of +12.2% year over year.Sales- Diabetes- Janumet - U.S.: $68 million compared to the $45.63 million average estimate based on three analysts. The reported number represents a change of +300% year over year.Sales- Oncology- Alliance revenue- Lynparza - U.S.: $174 million versus the three-analyst average estimate of $140.82 million. The reported number represents a year-over-year change of +13.7%.Sales- Oncology- Alliance Revenue- Lynparza: $370 million compared to the $321.44 million average estimate based on four analysts. The reported number represents a change of +16.7% year over year.Sales-Cardiovascular-Winrevair: $336 million versus the four-analyst average estimate of $343.79 million.Sales- Oncology- Alliance revenue- Lenvima: $265 million versus $244.01 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.Sales- Oncology- Keytruda: $7.96 billion compared to the $7.9 billion average estimate based on four analysts. The reported number represents a change of +9.4% year over year.Sales- Animal health: $1.65 billion versus $1.55 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.Sales- Vaccines- Gardasil: $1.13 billion compared to the $1.3 billion average estimate based on four analysts. The reported number represents a change of -54.6% year over year.Sales- Oncology- Welireg: $162 million versus $154.16 million estimated by four analysts on average.Sales- Virology- Lagevrio: $83 million versus $55.63 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -24.6% change.View all Key Company Metrics for Merck here>>>Shares of Merck have returned +6.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks